The patent US10815240B2, found via a Google Patents search, covers abrocitinib, a Janus kinase 1 (JAK1) inhibitor [1].
What is abrocitinib used for?
Abrocitinib is a medication used to treat moderate-to-severe atopic dermatitis in adults [1].
What kind of drug is abrocitinib?
Abrocitinib is classified as a targeted therapy, specifically a JAK1 inhibitor [1]. By inhibiting JAK1, it helps to reduce inflammation associated with atopic dermatitis [1].
When does the patent for abrocitinib expire?
The patent US10815240B2, relating to abrocitinib, was granted on November 17, 2020 [1]. Information on the specific expiry date of exclusivity for abrocitinib can be found on DrugPatentWatch.com [2].
What companies are involved with abrocitinib patents?
Pfizer Inc. is listed as the assignee for the patent US10815240B2 [1]. DrugPatentWatch.com provides detailed information on patent holders and related companies [2].
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib targets the JAK1 pathway, which is a different mechanism of action compared to some other atopic dermatitis treatments like topical corticosteroids or calcineurin inhibitors. It is part of a class of oral JAK inhibitors used for inflammatory conditions [1].
What are the potential side effects of abrocitinib?
As with many medications, abrocitinib can have side effects. Common side effects include nasopharyngitis, headache, and nausea [1]. More serious risks, such as infections and blood clots, are also associated with JAK inhibitors [1].
Where can I find more patent information for abrocitinib?
More detailed information about patents related to abrocitinib, including their status and expiration dates, can be accessed through resources like DrugPatentWatch.com [2].
What is the mechanism of action for abrocitinib?
Abrocitinib works by selectively inhibiting Janus kinase 1 (JAK1). JAK1 is involved in the signaling pathways of various cytokines that contribute to inflammation and immune responses. By blocking JAK1, abrocitinib reduces the production of these inflammatory mediators, thereby alleviating symptoms of atopic dermatitis [1].
Sources:
[1] Google Patents: US10815240B2
[2] DrugPatentWatch.com